These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 23652214)

  • 1. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
    Lacy M; Hauser M; Pliskin N; Assuras S; Valentine MO; Reder A
    Mult Scler; 2013 Nov; 19(13):1765-72. PubMed ID: 23652214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.
    Lanzillo R; Prinster A; Scarano V; Liuzzi R; Coppola G; Florio C; Salvatore E; Schiavone V; Brunetti A; Muto M; Orefice G; Alfano B; Bonavita V; Brescia Morra V
    J Neurol Sci; 2006 Jun; 245(1-2):141-5. PubMed ID: 16626758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study.
    Bergendal G; Fredrikson S; Almkvist O
    Eur Neurol; 2007; 57(4):193-202. PubMed ID: 17272938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current status of interferon beta-1b in multiple sclerosis therapy].
    Hartung HP
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
    Flechter S; Vardi J; Finkelstein Y; Pollak L
    Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b.
    Pliskin NH; Hamer DP; Goldstein DS; Towle VL; Reder AT; Noronha A; Arnason BG
    Neurology; 1996 Dec; 47(6):1463-8. PubMed ID: 8960728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
    J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis.
    Barak Y; Achiron A
    Eur Neurol; 2002; 47(1):11-4. PubMed ID: 11803186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
    Tur C; Montalban X; Tintoré M; Nos C; Río J; Aymerich FX; Brieva L; Téllez N; Perkal H; Comabella M; Galán I; Calle D; Sastre-Garriga J; Rovira A
    Arch Neurol; 2011 Nov; 68(11):1421-7. PubMed ID: 22084124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis.
    Amato MP; Portaccio E; Goretti B; Zipoli V; Battaglini M; Bartolozzi ML; Stromillo ML; Guidi L; Siracusa G; Sorbi S; Federico A; De Stefano N
    Arch Neurol; 2007 Aug; 64(8):1157-61. PubMed ID: 17698706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
    Goodin DS; Traboulsee A; Knappertz V; Reder AT; Li D; Langdon D; Wolf C; Beckmann K; Konieczny A; Ebers GC;
    J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):282-7. PubMed ID: 22193561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
    Feinstein A; O'Connor P; Feinstein K
    J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis.
    Selby MJ; Ling N; Williams JM; Dawson A
    Percept Mot Skills; 1998 Jun; 86(3 Pt 1):1099-106. PubMed ID: 9656314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
    Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
    Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.